|Nasdaq:||AAPL GOOG NFLX AMZN BIIB REGN IBB WYNN TSLA ALXN ILMN JAZZ CELG CHTR COST AMGN FFIV Z PCYC|
|Nyse:||V ACT UNP IBM IVV LNKD SPG AGN GS LMT CMI TWC MMM FDX CXO PX BA CVX NOC UTX|
|New Highs:||PSA AGN CXO MTB XEC FRT EQT HP CAT EOG SLG ZMH APH SIAL RRC HES MJN EMN SNDK TRW|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.